Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
List view / Grid view
acute myeloid leukaemia (AML)
A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
Researchers have found that the gene mesothelin can be targeted by new antibody-drug conjugates to treat acute myeloid leukaemia in children.
The fat molecule avocatin B, found in avocados, was shown to inhibit VLCAD, an enzyme vital for leukaemia cell metabolism.
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
CRISPR-Cas9 and stem cell technologies have been used to create a cellular model of acute myeloid leukaemia, revealing therapeutic targets.
Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.
A clinical study is to be launched after researchers found that a common and inexpensive drug may be used to counteract treatment resistance in patients with AML.
A possible new avenue for treatment of Acute Myeloid Leukaemia (AML) has opened up after US scientists pinpoint how the cancer spreads using excessive amounts of vitamin B6.
A pioneering team of scientists from Rice University has discovered that a particular combination of chemotherapeutics, including mitocans that target mitochondria, form a powerful treatment for acute myeloid leukaemia patients.
Researchers have found a molecule, which when deleted, increases leukaemia sensitivity to natural killer cells and is a drug target.
The epigenetic protein, EZH2, was found to delay the development of acute myeloid leukemia (AML) but also switches sides to maintain tumour growth...